Datasets:
ickma
/
sec_AA

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
198
2.89k
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. is unpredictable and requires successful completion of extensive clinical trials which typically takes many years, depending upon numerous factors, including the type, complexity and novelty of the ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Disruptions at the FDA and other agencies, including del...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. for their applications. While the FDA has largely caught up with domestic preapproval inspections, it continues 56 Table of Contents to work through its backlog of foreign inspections. However, ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. which we may market, promote and advertise the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy (“REMS”) plan a...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described a...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amoun...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. operations, which may lead to slower response times and longer review periods, potentially affecting our ability to obtain regulatory approval for our product candidates. In addition, the impact of ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. design, implementation or results of our clinical trials; the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe or effective, are on...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. proposed indication is acceptable; the FDA, EMA or other comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes, test procedures and spe...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. , EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction. Our clinical trials have been and may in the future be...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. different. There can be no assurance that any United States or foreign regulatory authority would accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any app...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. evaluation of the benefit-risk profiles of new medicinal products, and determination of marketing authorization across different jurisdictions. Uncertainty in the regulatory framework could also res...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. obtaining regulatory approval of our product candidates in other jurisdictions. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that w...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. in other jurisdictions. The regulatory approval 58 Table of Contents processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United States, as wel...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. market will be reduced and our ability to realize the full market potential of a product candidate will be harmed. Following Brexit, to the extent we conduct any operations in the United Kingdom, w...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Clinical Trials) Regulations 2004, which transposes the Clinical Trials Directive into domestic law. Consequently, the requirements and obligations that relate to the conduct of clinical trials in th...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. marketing approval for could be, subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we or our collaborators fail to comply with reg...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. authority to require labeling changes based on new safety information and to require post-marketing studies or clinical trials to evaluate serious safety risks related to the use of a drug. For exam...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. , labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing reg...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. in all areas of regulatory compliance, including manufacturing, production, and quality control. FYARRO is, and if marketing approval of any other product candidate we may develop in the future is ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. actions, which may include, among other things, the issuance of a Warning Letter and assessing civil monetary penalties. The product may also be deemed misbranded. 59 Table of Contents FYARRO doe...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of products to ensure products are marketed ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or criminal prosecution, including False Claims Act liability, restrictions on our operations and other operating requirements through consent decrees or corporate integrity agreements, debarment, e...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. result in delays in product development or commercialization, or increased costs to assure compliance. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requiremen...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or partial suspension of production; imposition of restrictions on operations, including costly new manufacturing requirements; requirement to establish or modify a REMS; requirement to conduct p...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. existing contracts, exclusion from participation in federal health care programs; or injunctions or the imposition of civil or criminal penalties, including False Claims Act liability. The holder ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses of FYARRO or any othe...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. As such, we may not promote our products for indications or uses for which they do...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of FYARRO and any other product candidate that we may develop in the future, if approved, we cou...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. develop or work with collaborators to develop or obtain access to companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit fro...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. at the same time the product candidate is approved. To date, the FDA has required marketing approval of all companion diagnostic tests for cancer therapies. Various foreign regulatory authorities al...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. new indication that we may develop, whether before or concurrently with approval of such product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining ap...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of a companion diagnostic for our product candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim. Also, to the extent oth...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. . It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. future product candidate or new indication, or experience delays in doing so, the development of such product candidate may be adversely affected, the product candidate may not obtain marketing appr...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or new indication. or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of any such future product candidate we may develop. A F...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of adult and adolescent patients with malignant solid tumors harboring TSC1 & TSC2 alterations and of patients with advanced malignant PEComa, respectively. While the FDA granted us Priority Revie...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Track designation for additional cancer indications or other diseases, and we may not be successful in securing such additional designation or in expediting development if such designations were rec...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. specific indication for which it is being studied. If FYARRO for the investigation for the treatment of patients with malignant solid tumors harboring TSC1 & TSC2 alterations, or FYARRO for any ot...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. not guarantee qualification for the FDA’s priority review procedures and we may not experience a faster development process, review or approval compared to conventional FDA procedures. In December ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. sponsor may request the FDA to designate our product candidate as a Breakthrough Therapy at the time of, or any time after, the submission of an IND for the product candidate. For product candidates...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and taking steps to ensure that the des...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that FYARRO will receive regulatory approval in the United St...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasona...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not approve any other applic...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. position that the orphan drug exclusivity only applies to the approved use or indication within an eligible disease, and not to all uses or indications within the entire disease or condition. In par...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. notice in the Federal Register to clarify that while the agency complies with the 63 Table of Contents court’s order in Catalyst , the FDA intends to continue to apply its longstanding interpre...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain regulatory approval of any product candidate for which we have obtained orphan drug d...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later d...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or orphan drug exclusivity for any other indication or regulatory approval for FYARRO for any other orphan population, or we may be unable to successfully commercialize FYARRO for such orphan popula...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. may not have a favorable risk/benefit assessment in the respective orphan indication. If we are unable to obtain regulatory approval for FYARRO in any other orphan population for which we obtain or...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. verify clinical benefit, or if we do not comply with rigorous PMRs, the FDA may seek to withdraw accelerated approval. Where possible, we plan to pursue accelerated development strategies in areas ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predic...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit, the FD...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements. Prior to seeking such accel...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or under another expedited regulatory designation (e.g., breakthrough therapy designation), there can be no assurance that such submission or application will be accepted or that any expedited devel...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. government regulations may be enacted that could prevent, limit or delay regulatory approval of FYARRO for advanced malignant PEComa outside the United States and for any additional indications that...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. , as amended by the Health Care and Education Reconciliation Act of 2010 (the “ACA”), was passed, which substantially changes the way healthcare is financed by both the government and private insurer...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. former Trump administration to repeal or replace certain aspects of the ACA. In June 2021, the Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismiss...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary f...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. candidates that we may develop if the future, if approved, and accordingly, our financial operations. 65 Table of Contents Moreover, there has been heightened governmental scrutiny recently over ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July 2021, the Biden administration released an executive order, “Promoting Competit...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their dru...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. adverse effect on our business. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. products for which we may receive regulatory approval in the future. Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (“R...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price tha...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA’s approval process may significantly delay or prevent regulatory approval, as well as subject us to ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Additionally, the collection and use of health data in the European Union is governed by the General Data Protection Regulation (the “GDPR”), which extends the geographical scope of European Union ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. set at $2,500 per violation (i.e., per person) or $7,500 per intentional violation and (b) authorizes private lawsuits to recover statutory damages for certain data breaches. While it exempts some d...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely m...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, including delays or disruptions due to the COVID-19 pandemic, travel restrictions, ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. , in response to the COVID-19 pandemic, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bior...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through 67 Table of Contents which we market, sell and distribute our p...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for ea...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal govern...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the b...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or maki...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating complianc...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. information regarding ownership and investment interests held by physicians and their immediate family members; our failure to submit required information timely, accurately, and completely may resu...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. we fail to comply with an applicable state law requirement, we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of our business. We may be subject to private “qui tam” actions brought by individual whistleblowers on behalf of the federal or state governments. If we were to grow our business and expand our sa...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. our business. Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy laws and regulations will involve on-goi...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and the curtailment or restructuring of our operations. Any of the foregoing consequences could seriously harm our business and our financial results. Defending against any such actions can be costl...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or other improper activities, including noncompliance with regulatory standards and requirements. We are exposed to the risk that our employees, independent contractors, consultants, commercial col...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may r...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending our self or asserting our rights, those action...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. on our business. We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting require...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. any contamination at our current or past facilities and at third-party facilities, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incu...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other san...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and kee...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. are subject to regulation under the FCPA. Recently, the SEC and DOJ have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our busine...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our pr...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. to comply with export and import regulations, and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. supplies, as well as the costs of materials and products imported into the United States. Tariffs, trade restrictions or sanctions imposed by the United States or other countries, including as a res...